Rentschler Biotechnologie extends mammalian cell culture manufacturing capacity

German company Rentschler Biotechnologie, a contract manufacturing organisation for the development and production of biopharmaceuticals in mammalian cells, has begun operating a 2,500-litre multi-process production suite.

Rentschler Biotechnologie now has nine stand-alone GMP suites with volumes of 30, 250, 500 and 2,500 litres, allowing the production of material for clinical trials and for market supply.

The new 2,500-litre bioreactor is designed to allow batch, fed-batch, or perfusion cell culture processes to be run. Protein purification is performed in two suites for pre- and post-virus inactivation, respectively.

Using its modern GMP production suites, Rentschler Biotechnologie offers comprehensive services "from gene to drug product" and can develop tailored solutions through all phases of development and production. Its "preferred partnership" agreement with Boehringer Ingelheim means that customers requiring higher production capacities have easy access to Boehringer's large-scale bioreactor volumes of up to 15,000 litres.